Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
A Medication Safety Initiative
Staff Writers
Pfizer, Inc will be launching a website, now under beta construction, on medication safety to help consumers weigh drug risks and benefits. This is considered, by some, an unusual move in an industry often criticized as using marketing practices that oversell drug benefits and downplay risks.
Patient Advocacy
According to the Associated Press on September 16, Pfizer plans to promote the site by working with medical and patient advocacy groups, as well as with online advertising on websites targeting medical professionals and patients.
Assessment
The detailed future site will include sections written for patients and for health professionals, with plain-English explanations, engaging graphics and clips of video hosts discussing important points. It will also have a prominent link to information about how to report a drug side effect to Medwatch, the Food and Drug Administration [FDA] reporting program.
Conclusion
Your thoughts and comments are appreciated. Is it about time to launch this patient safety initiative; or far too late?
Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759
Physician Financial Planning: http://www.jbpub.com/catalog/0763745790
Medical Risk Management: http://www.jbpub.com/catalog/9780763733421
Healthcare Organizations: www.HealthcareFinancials.com
Health Administration Terms: www.HealthDictionarySeries.com
Physician Advisors: www.CertifiedMedicalPlanner.com
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com or Bio: www.stpub.com/pubs/authors/MARCINKO.htm
Subscribe Now: Did you like this Executive-Post, or find it helpful, interesting and informative? Want to get the latest E-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.
Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos
Copyright 2008 iMBA Inc: All rights reserved, USA, unless otherwise noted. Use is restricted to Executive-Post subscribers only. No redistribution is allowed. To avoid violation of iMBA Inc copyright restrictions and redistribution policy, please register for your own free Executive-Post membership. Detailed information and registration links are available at:
Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos
Referrals: Thank you in advance for your electronic referrals to the Executive-Post
Share this:
Filed under: Drugs and Pharma, Quality Initiatives | Tagged: FDA, Pfizer |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Finally … Pfizer
Did you know that Pfizer will become the latest drug maker to publicly disclose the payments it makes to doctors, as the industry has come under fresh fire for its undue influence and could face toughened legislation?
According to the Wall Street Journal, February 9, 2009, the New York drug maker follows Eli Lilly & Co., Merck & Co. and GlaxoSmithKline PLC in pledging its commitment to transparency. Pfizer will report all payments to doctors of more than $500 for consulting and speaking arrangements and will also make public the money it pays them to participate in its clinical trials.
As reported on this ME-P, Eli Lilly, was the first in the industry to open its books and discloses payments of more than $500, and plans to make clinical trial payments public in 2011.
Hope
LikeLike